Lupin: Generics booster - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Lupin: Generics booster

May 21, 2002

Lupin Ltd. has ended FY02 with 6% growth in sales and an encouraging 48% jump in PBT. Net profit however, grew by 20% on account of new accounting policy on deferred taxation. The growth in sales was fuelled by higher export growth. Operating margins jumped by more than 310 basis points. During the year, the company initiated several measures to achieve roboust growth in exports and push R&D as a key area of growth, going forward.

(Rs m)FY01FY02% Change
Sales 9,029 9,569 6.0%
Other Income 86 85 -1.6%
Expenditure 7,682 7,836 2.0%
Operating Profit (EBDIT) 1,347 1,733 28.7%
Operating Profit Margin (%)14.9%18.1% 
Interest 597 622 4.2%
Depreciation 185 232 25.1%
Profit before Tax 650 964 48.2%
Tax 50 242 384.0%
Profit after Tax/(Loss) 600 722 20.3%
Net profit margin (%)6.6%7.5% 
No. of Shares (m)40.140.1 
Diluted Earnings per share15.017.7 
P/E (at current price) 6.1 

The highlight of the results was a 34% rise in exports on the back of a sharp rise in contribution from generics exports to US and European markets, which increased by more than 6 fold. Formulations business recorded a growth of 3%. While export formulations registered a drop of more than 44% (though on a smaller base), domestic formulations growth was 6%. Domestic formulations sales were affected by downward revision in prices of rifampicin formulations on account of the new DPCO order.

ParticularsFY01FY02% Change
Generics 93 728 680.2%
API/ Bulk Drugs 4,718 4,488 -4.9%
Formulations 4,163 4,283 2.9%
Others 54 70 27.9%
9,029 9,569 6.0%

The company launched several new products during the year particularly in the cardiovascular, cephalosporins and anti-TB segments. In the Cephalosporin segment, the company is steadily consolidating market share with the introduction of new products at the same time focusing upon its current product portfolio. The cephalosporin segment registered a growth of around 8% during the year. It has launched 15 products during the year. Lupin plans to introduce 70-80 products in the span of 3 years, which should reduce its dependence on the anti-TB segment. With new product launches, the cardiovascular segment registered a 50% growth over the last year.

Exports now contribute around 32% (up from 24% for 9m FY02) to the company's total turnover. Going forward, cephalosporins would be a key focus area for exports. The company intends to explore the partnership route to enter the generic market by tieing up with large generic companies in the US. In the generic business, the company has tied up with three generic marketing companies viz, Merck Generics, ABP and Apcotex. Lupin has already started supplying Cefotaxime and Cefuroxime Axetil in the API form to its marketing alliance in the US. Currently, Ranbaxy has marketing exclusivity for Cefuroxime Axetil in the US and Apcotex, Lupin's partner is expected to start marketing the drug by July'02 this year. At least till mid 2003, Apcotex is expected to be the sole generic competitor to Ranbaxy and thus, the order size for bulk Cefuroxime is expected to provide significant contribution to Lupin in the current year.

The company has applied for 2 ANDA's (Abbreviated New Drug Application) with the US FDA for Ceftriaxone injection and Cefotaxime injection and it claims to have 'first to file' status on the former. Lupin plans to file 6-7 ANDA's for the US markets this year, with a target of creating a product basket of 25 products over 3 years.

Lupin has now recognized R&D as a key thrust area. The company has established a state-of-the-art R&D centre spread over an area of 19 acres at Pune. The research activity of the company is focused in such a manner to provide solutions to both immediate and post 2005 research requirements. The company now spends almost 5% of its total revenues on research. Lupin has 6 molecules in the pipeline, both on NCE and NDDS platform. All molecules are in early pre-clinical stages and it would take time (atleast late 2003) before one can expect revenues from out licensing.

At the current market price of Rs 108, the stock is trading at 6x its earnings for FY02. The current acceleration in its research iniatitives, sales and margins growth and breakthrough in the generics business are expected to prove as good triggers for the stock in the near term. The stock is also attractively priced when compared to its peers. However, a high capital gearing ratio (1.6x approx) is one of the key areas of concern. Debt burden of the company has jumped to Rs 622 m eating away more than one third of its operating profits. Moreover, the capital structure of the company also has significant preference shares, which carries a fixed dividend burden.

Equitymaster requests your view! Post a comment on "Lupin: Generics booster". Click here!

  

More Views on News

LUPIN 2020-21 Annual Report Analysis (Annual Result Update)

Oct 19, 2021 | Updated on Oct 19, 2021

Here's an analysis of the annual report of LUPIN for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Dec 3, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS